aTyr Announces Phase 2 Study of SSc-ILD Drug
The expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
The expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
A genetic variant in a surfactant-producing protein led to a fatal case of interstitial lung disease in a two-year-old child, according to an analysis of the child's lung tissue.
The Cleveland Clinic recently received a $3 million grant to develop an improved risk-modeling approach to help prioritize patients for lung transplant.
Healthcare providers are increasingly interested in the role of ECMO to support critically ill patients in the current pandemic.
Read MoreA team of researchers at the University of Illinois at Urbana-Champaign has developed tiny sensors that measure oxygen transport in bovine lung tissue. The study, which establishes a new framework for observing the elusive connection between lung membranes, oxygen flow and related disease, is published in the journal Nature Communications.
Read MorePeople with HIV are more likely to experience interstitial lung abnormalities and interstitial lung disease (ILD), according to new research.
Read MoreA cut to the tax coal companies pay to fund a trust for sick miners will cost taxpayers at least $15 billion by 2050, according to a new report from a national watchdog group.
Read Morefindings come from a study published in the American Journal of Preventive Medicine. Researchers tracked new lung disease among people who smoke and vape.
Read MorePulmonary fibrosis (PF) is a complex interstitial lung disease that afflicts an estimated 100,000 Americans, with 30-40,000 new cases diagnosed each year.
Read MoreThe FDA has granted Ofev (nintedanib) a breakthrough therapy designation for chronic fibrosing interstitial lung disease, according to Boehringer Ingelheim.
Read MoreThe US FDA has approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD).
Read MoreOfev (nintedanib) reduced the annual rate of FVC decline in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).
Read MoreBayer Pharmaceuticals is terminating its Phase II study investigating riociguat in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias.
Read MoreInterstitial lung diseases (ILDs) comprise a spectrum of related disorders and correctly diagnosing and treating this diverse group is a challenge to clinicians.
Read More